Cargando…
Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients
BACKGROUND. Type 2 diabetes mellitus (T2DM) is prevalent in patients undergoing heart transplant, and in those without preexisting T2DM, posttransplant diabetes mellitus may develop. Both T2DM and posttransplant diabetes mellitus have been associated with increased morbidity and mortality following...
Autores principales: | Cehic, Matthew G., Muir, Christopher A., Greenfield, Jerry R., Hayward, Christopher, Jabbour, Andrew, Keogh, Anne, Kotlyar, Eugene, Muthiah, Kavitha, Macdonald, Peter S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511439/ https://www.ncbi.nlm.nih.gov/pubmed/31165085 http://dx.doi.org/10.1097/TXD.0000000000000885 |
Ejemplares similares
-
Value of Renal Histology in Predicting Cardiorenal Outcomes in Heart Transplant–listed Patients
por: Barua, Sumita, et al.
Publicado: (2022) -
Reversibility of Frailty After Bridge-to-Transplant Ventricular Assist Device Implantation or Heart Transplantation
por: Jha, Sunita R., et al.
Publicado: (2017) -
Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial
por: Raven, Lisa Mary, et al.
Publicado: (2023) -
THU298 Effect Of SGLT2 Inhibition On Metabolic, Cardiac And Renal Outcomes In Heart Transplant Recipients (EMPA-HTx study): Protocol And Study Design
por: Raven, Lisa M, et al.
Publicado: (2023) -
De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)